Medicinal cannabis company Cann Global entered into a strategic alliance with TGA & GMP approved manufacturer, Bio Health Pharmaceuticals, to fast-track the introduction of its product range to market.
The agreement will see Bio Health manufacture Cann Global’s medical cannabis formulations and nutraceutical hemp food consumables at its state of the facilities in Sydney, saving millions to Cann Global in manufacturing costs in the process.
Cann Global’s Production and Development Manager Peter Edwards said the company’s products will be distributed both locally and internationally, with a particular focus on the established markets of Hong Kong, Japan and Korea.
“Bio Health Pharmaceuticals is a genuinely dynamic company, innovative, Asian focused, well respected and have impeccable regulatory credentials,” Mr Edwards continued.
“High quality pharmaceutical and nutraceutical manufacturing practices are available to Cann Global now, rather than later.”
“In addition to now having the ability to immediately mass produce the Canntab and Pharmocann medical Cannabis products, together, we are about to produce high volume co-branded nutraceutical products under the Bio Health Pharmaceuticals and VitaHemp banner, initially targeting the mature Hemp markets in Hong Kong, Japan and Korea. ”
He said the deal with Bio Health could also open up new opportunities with to leverage relationships with chemists, health food conglomerates and supermarket chains in the region.
“There are positives for both companies in existing markets, whilst exploring new, particularly large Asian chemist and health food conglomerates, including in the massive Chinese markers,” Mr Edwards concluded.
